ABCG2 and neoplasm: To investigate the tumor therapeutic efficiency of systemic siRNA delivery in vivo, nude mice bearing MCF-7/S or MCF-7/ADR tumor xenografts were subjected to various formulations at 1.3 mg/kg ABCG2-siRNA and 5 mg/kg ADR every 3 days.